TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17038828
Drug: Respiratory route
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory route of measles vaccine administration (for vaccinees over 9 months of age)
Study: 17038828
Drug: Respiratory route
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory route of measles vaccine administration (Edmonston Zagreb strain)
Study: 17038828
Drug: Aerosolized EZ
Normalized name: Jock-Eze
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized EZ vaccine
Study: 7485344
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotic therapy)
Study: 6840161
Drug: Cadralazine (ISF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (ISF 2469) 7.5 mg
Study: 6840161
Drug: Cadralazine (ISF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (ISF 2469) 15 mg
Study: 6840161
Drug: Cadralazine (ISF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (ISF 2469) 20 mg
Study: 6840161
Drug: Cadralazine (ISF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (ISF 2469) 30 mg
Study: 19016798
Drug: Omalizumab (Xolair)
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab (Xolair) in combination with depigmented SIT (Depigoid)
Study: 11350520
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B D9
Study: 3591956
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g protein, 30 g fat, and 30 g carbohydrate (P)
Study: 3591956
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g carbohydrate, 30 g fat, and 30 g protein (C)
Study: 2660991
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with dipyridamole
Study: 18972076
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of Systane Lubricant Eye Drops
Study: 14727703
Drug: Polymer gel
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer gel sock in conjunction with the removable rigid dressing
Study: 10378544
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (42 microg per actuation)
Study: 10378544
Drug: Extended-release oral
Normalized name: Carbinoxamine Maleate Extended-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oral theophylline (titrated to serum levels of 10 to 20 microg/mL)
Study: 8681669
Drug: High-dose fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fenoterol (5 mg)
Study: 8681669
Drug: Low-dose fenoterol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fenoterol (1 mg)
Study: 7924541
Drug: Nonpharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapy
Study: 6143849
Drug: Corgard (nadolol)
Normalized name: nadolol Oral Tablet [Corgard]
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corgard (nadolol) 80 mg
Study: 27036991
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (200 mg emtricitabine with 10 mg or 25 mg tenofovir alafenamide)
Study: 27036991
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate)
Study: 20192914
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (1000 microg daily)
Study: 12071996
Drug: 10% cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% cocaine spray
Study: 7611550
Drug: Primaquine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (0.5 mg/kg every other day for 16-19 weeks)
Study: 7611550
Drug: Chloroquine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (5 mg/kg weekly for 16-19 weeks)
Study: 21717823
Drug: Program A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program A (modified US Department of Agriculture food pyramid diet and rice protein powder supplement)
Study: 12621482
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus stem-cell transplantation
Study: 9126306
Drug: Granisetron, methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron, methylprednisolone (250 mg/body), and droperidol (0.5 ml/body)
Study: 8471555
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate (250 mg/m2) and 5-fluorouracil (500 mg/m2) followed by leucovorin (15 mg x 8) (MFL)
Study: 8471555
Drug: Sequential 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential 5-fluorouracil (500 mg/m2) followed by leucovorin (60 mg/m2) (FLv)
Study: 2956392
Drug: 15 mmol
Normalized name: dibasic potassium phosphate 15 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mmol sodium/day (plus frusemide, 40 mg on day 1)
Study: 30267987
Drug: Ixabepilone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (40 mg/m2)
Study: 15913717
Drug: Rectal measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal measurement of intra-abdominal pressure (Prec)
Study: 10198865
Drug: Cooled intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled intraocular irrigating solution (approximately 10 degrees C)
Study: 10198865
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature irrigating solution
Study: 2180471
Drug: multidrug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multidrug chemotherapy (MDC)
Study: 31123069
Drug: Low-sodium peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium peritoneal dialysis fluid (125 mmol/L Na)
Study: 31123069
Drug: Standard-sodium peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-sodium peritoneal dialysis fluid (134 mmol/L Na)
Study: 28104097
Drug: 5% NaHCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% NaHCO3 and distilled water solution at 40-45°C
Study: 17177056
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day for 2 weeks)
Study: 22185963
Drug: HX575 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX575 (subcutaneous administration)
Study: 20685806
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (transcranial direct current stimulation and visual illusion)
Study: 18204328
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of AT
Study: 7737266
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day for at least 1 year
Study: 7737266
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (lipid-lowering diet only)
Study: 2405735
Drug: pH-adjusted bupivacaine
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-adjusted bupivacaine with hyaluronidase 15 units/ml (pH 6.82 +/‐ 0.09)
Study: 18173093
Drug: Xylitol (6.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (6.2 g/day)
Study: 8018401
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy with doxorubicin
Study: 8018401
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy without doxorubicin
Study: 2644855
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ferrous sulfate twice daily for 16 weeks
Study: 1115173
Drug: Non-steroid IUD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid IUD
Study: 28035868
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once daily for 24 weeks
Study: 23639513
Drug: Olmesartan/Amlodipine fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine fixed-dose combination (OA)
Study: 23639513
Drug: Amlodipine double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine double dose (DA)
Study: 12716247
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation (LA)
Study: 3900975
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg q.o.d.)
Study: 3900975
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg q.o.d.)
Study: 27311399
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT) with level V lymphatics (LVN) included
Study: 27311399
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT) with level V lymphatics (LVN) omitted
Study: 18005381
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 20 ml levobupivacaine 0.625 mg/ml and fentanyl 2 microg/ml
Study: 16099291
Drug: C4A-rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C4A-rich plasma priming (20 mL/kg)
Study: 16099291
Drug: C4A-free plasma
Normalized name: Antihemophilic factor recombinant plasma/albumin free
DrugBank: Moroctocog alfa (DB13999)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C4A-free plasma priming (20 mL/kg)
Study: 11868640
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight 4000 g or more
Study: 8732492
Drug: L-lysine
Normalized name: L-Lysine
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-lysine
Study: 1553671
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg trinitroglycerine patches
Study: 31087715
Drug: Any antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antibiotics use
Study: 31087715
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for respiratory infections
Study: 31087715
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for urinary tract infections
Study: 31087715
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for skin and soft tissue infections
Study: 31087715
Drug: Beta-lactamase sensitive
Normalized name: Beta-lactamase sensitive penicillins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactamase sensitive penicillin (more than two prescriptions)
Study: 27648792
Drug: Ice/gel pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice/gel pack cryotherapy wrap
Study: 2098653
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/daily)
Study: 28248854
Drug: Conventional chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional chest physical therapy (CCPT)
Study: 25787020
Drug: Losartan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (mean 43 ± 12 mg/day)
Study: 20160397
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day pioglitazone for 12 weeks
Study: 20160397
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day metformin for 12 weeks
Study: 17089155
Drug: Microwave diathermy
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave diathermy treatment (passive hyperthermia) increasing muscle temperature to over 40 degrees C, 16-20 hours prior to exercise.
Study: 30796001
Drug: Polycarbonate groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycarbonate groups (all treatment methods)
Study: 30796001
Drug: PMMA groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMMA groups (all treatment methods)
Study: 29020247
Drug: Arterolane maleate
Normalized name: maleate
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg once daily for 3 days
Study: 29020247
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) twice daily for 3 days
Study: 24854088
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (clobetasol propionate 0.05% ointment) applied for the first 2 days, followed by petrolatum jelly for the rest of the week.
Study: 21729165
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (5-ALA) PDT at 25 mW/cm2
Study: 21729165
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (5-ALA) PDT at 50 mW/cm2
Study: 21729165
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (5-ALA) PDT at 75 mW/cm2
Study: 16253380
Drug: Multiple actrapid
Normalized name: Human Actrapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple actrapid and NPH insulin injections
Study: 16253380
Drug: Sulphonylurea and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea and metformin+/‐acarbose
Study: 14967744
Drug: Adjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiotherapy (carboplatin 30 mg/m2 on days 1-5 of weeks 1, 3, and 5; radiotherapy 54.0 Gy to all risk volumes plus 10.0 Gy to high-risk volumes; 5 daily fractions of 1.8 Gy each per week)
Study: 11051743
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (nitrosorbid, cardiket) 80 mg/day
Study: 11051743
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate (mono mac) 51.5 mg/day
Study: 8223839
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation containing metoprolol 100 mg and hydrochlorothiazide 12.5 mg
Study: 8223839
Drug: Conventional combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combination tablet
Study: 3532593
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine b.i.d. (49 patients)
Study: 3532593
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine nocte (47 patients)
Study: 26524709
Drug: Elevated hsTnT
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated hsTnT (≥14 ng/L)
Study: 16583831
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/day plus MPA 2.5 mg/day (n = 7)
Study: 16583831
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (n = 13)
Study: 7552059
Drug: Empirical titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical titration of electrical stimulus for ECT
Study: 7552059
Drug: Dose predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose predictive methods from two different ECT equipment instruction manuals
Study: 2316883
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (3 mg/min)
Study: 6444861
Drug: Lotion with
Normalized name: LOTION WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion with hydrocortisone acetate ('Actinac')
Study: 6444861
Drug: Lotion without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lotion without hydrocortisone acetate
Study: 30773191
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 3 to 9 ml of iodined PolyEthylene Glycol (PEG) hydrogel
Study: 31322589
Drug: Elgydium Protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elgydium Protection caries toothpaste used for brushing teeth twice a day for 6 months
Study: 28683939
Drug: Scoring balloon
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoring balloon pre-dilation before drug-coated balloon (DCB) therapy
Study: 28683939
Drug: Standard DCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DCB therapy
Study: 23932219
Drug: Multistrain preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistrain preparation of lactobacilli and bifidobacteria (6 × 10^10 organisms, one per day for 21 days)
Study: 23932219
Drug: Multistrain preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistrain preparation of lactobacilli and bifidobacteria
Study: 16228108
Drug: Intra-articular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tenoxicam 20 mg once weekly for 1-3 weeks
Study: 16228108
Drug: Oral tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenoxicam 20 mg/day for 3 weeks
Study: 9305716
Drug: CsA-based quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-based quadruple induction therapy using an antilymphocyte globulin preparation (ATG)
Study: 9305716
Drug: CsA-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-based triple therapy
Study: 9305716
Drug: CsA-based quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-based quadruple induction therapy using an interleukin-2 receptor antibody (BT563)
Study: 8382131
Drug: Sinorphan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan (100 mg)
Study: 3532209
Drug: Intracervical Prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Prostaglandin E2 (0.5 mg in 2.5 ml triacetin-gel)
Study: 27671868
Drug: Double-low imaging
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-low imaging protocol (80-100 kV, 200 mAs, iohexol 300 mg iodine/ml, 1-1.5 ml/kg)
Study: 27671868
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT protocol (120 kV, 200-300 mAs, iopamidol 370 mg iodine/ml, 1-1.5 ml/kg)
Study: 8703882
Drug: Argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon green laser treatment (n = 79)
Study: 8703882
Drug: Krypton red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton red laser treatment (n = 72)
Study: 2537795
Drug: Captopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (10 mg i.v. bolus followed by 10 mg/hr constant infusion)
Study: 2537795
Drug: Human ANF
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human ANF (99-126) infusion
Study: 25347418
Drug: SC +
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC + pharmaceutical medication management
Study: 22923258
Drug: Dexmedetomidine 0.1
Normalized name: dexmedetomidine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.1 μg/kg
Study: 22923258
Drug: Control (Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Dexmedetomidine 0 μg/kg)
Study: 20940335
Drug: Betahistine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (24 mg b.i.d.)
Study: 22353021
Drug: Wechsler Adult
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wechsler Adult Intelligence Scale‐Fourth Edition (WAIS‐IV) administered at baseline and again either 3 or 6 months later
Study: 9638029
Drug: 75 g.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g.kg‐1 load
Study: 9638029
Drug: 95 g.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 g.kg‐1 load
Study: 8032079
Drug: Tamoxifen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (60 mg/die)
Study: 2574550
Drug: Cetirizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (20 mg QD for two days)
Study: 2574550
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg BID for 1 week)
Study: 27895845
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate pneumococcal vaccine
Study: 22221277
Drug: Comprehensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive intervention that paired behavioral treatment with naltrexone
Study: 18499110
Drug: Melatonin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (4 mg prolonged release)
Study: 31493163
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg every 2 weeks
Study: 28774898
Drug: trabectedin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: trabectedin 1.5 mg/m2 as a 24-hour continuous intravenous infusion once every 3 weeks
Study: 28774898
Drug: dacarbazine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: dacarbazine 1,000 mg/m2 i.v. once every 3 weeks
Study: 21418785
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 25 mg twice weekly
Study: 17420365
Drug: Intracameral or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral or intravitreal injection of 40 microg of gentamicin sulfate and 45 microg of clindamycin
Study: 17420365
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection